10x Genomics Stock Current Valuation
| TXG Stock | USD 15.30 0.99 6.92% |
Valuation analysis of 10X Genomics helps investors to measure 10X Genomics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -32.21. The current Enterprise Value Multiple is estimated to decrease to -32.21. Fundamental drivers impacting 10X Genomics' valuation include:
Price Book 2.3966 | Enterprise Value 1.4 B | Enterprise Value Ebitda (40.69) | Price Sales 2.7508 | Forward PE 196.0784 |
Undervalued
Today
Please note that 10X Genomics' price fluctuation is not too volatile at this time. Calculation of the real value of 10X Genomics is based on 3 months time horizon. Increasing 10X Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the 10X stock is determined by what a typical buyer is willing to pay for full or partial control of 10X Genomics. Since 10X Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of 10X Stock. However, 10X Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.3 | Real 25.95 | Target 60.33 | Hype 15.1 | Naive 11.7 |
The real value of 10X Stock, also known as its intrinsic value, is the underlying worth of 10X Genomics Company, which is reflected in its stock price. It is based on 10X Genomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of 10X Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of 10X Genomics helps investors to forecast how 10X stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of 10X Genomics more accurately as focusing exclusively on 10X Genomics' fundamentals will not take into account other important factors: 10X Genomics Company Current Valuation Analysis
10X Genomics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current 10X Genomics Current Valuation | 1.42 B |
Most of 10X Genomics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 10X Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
10X Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for 10X Genomics is extremely important. It helps to project a fair market value of 10X Stock properly, considering its historical fundamentals such as Current Valuation. Since 10X Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of 10X Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of 10X Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
10X Current Valuation Historical Pattern
Today, most investors in 10X Genomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various 10X Genomics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of 10X Genomics current valuation as a starting point in their analysis.
10X Genomics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, 10X Genomics has a Current Valuation of 1.42 B. This is 90.11% lower than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 91.46% higher than that of the company.
10X Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 10X Genomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 10X Genomics could also be used in its relative valuation, which is a method of valuing 10X Genomics by comparing valuation metrics of similar companies.10X Genomics is currently under evaluation in current valuation category among its peers.
10X Genomics Current Valuation Drivers
We derive many important indicators used in calculating different scores of 10X Genomics from analyzing 10X Genomics' financial statements. These drivers represent accounts that assess 10X Genomics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of 10X Genomics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.0B | 14.3B | 16.4B | 4.1B | 6.6B | 5.2B | |
| Enterprise Value | 2.6B | 13.7B | 15.9B | 4.0B | 6.3B | 5.0B |
10X Genomics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, 10X Genomics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to 10X Genomics' managers, analysts, and investors.Environmental | Governance | Social |
10X Fundamentals
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 1.42 B | ||||
| Shares Outstanding | 107 M | ||||
| Shares Owned By Insiders | 2.16 % | ||||
| Shares Owned By Institutions | 94.41 % | ||||
| Number Of Shares Shorted | 7.61 M | ||||
| Price To Book | 2.40 X | ||||
| Price To Sales | 2.75 X | ||||
| Revenue | 618.73 M | ||||
| Gross Profit | 396.02 M | ||||
| EBITDA | (205.11 M) | ||||
| Net Income | (255.1 M) | ||||
| Cash And Equivalents | 499.73 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 95.37 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 5.97 X | ||||
| Cash Flow From Operations | (15.2 M) | ||||
| Short Ratio | 3.26 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Price To Earnings To Growth | 0.13 X | ||||
| Target Price | 20.29 | ||||
| Number Of Employees | 1.26 K | ||||
| Beta | 1.87 | ||||
| Market Capitalization | 1.73 B | ||||
| Total Asset | 965.14 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 468.86 M | ||||
| Net Asset | 965.14 M |
About 10X Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 10X Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out 10X Genomics Piotroski F Score and 10X Genomics Altman Z Score analysis. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 5.261 | Quarterly Revenue Growth (0.01) | Return On Assets (0.11) | Return On Equity (0.25) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.